29 Nov 2016 | Infection Prevention & Control
The goal of the Health Quality & Safety Commission's Surgical Site Infection Improvement (SSII) Programme is the reduction of surgical site infections in cardiac and orthopaedic surgery. The programme has made significant strides in improving the dose, timing and duration of surgical prophylaxis as well as achieving near universal use of alcohol-based skin preparation agents.
To date, the programme has followed ~28,000 hip and knee joint replacements and observed 340 surgical site infections – a rate of 1.2 percent. Analysis of the surgical site infection microbiology shows that 45 percent are due to staphylococcal infection.
Since the SSII programme began, several studies have reported the benefit of adding an 'anti-staphylococcal' bundle to reduce surgical site infections caused by staphylococci, notably Staphylococcus aureus. Because of the observed burden of staphylococcal infection in New Zealand patients, the Commission had a literature review undertaken to summarise data through to the end of 2015. The meta-analysis report, conducted by the Royal Australasian College of Surgeons, will be available on the Commission’s website following publication in a peer reviewed journal. A copy is available on request by emailing SSIIP@hqsc.govt.nz.
The Commission is evaluating the option of adding interventions related to staphylococcal decolonisation to the SSII Programme.
A discussion paper about the anti-staphylococcal bundle (PDF, 1.48MB) been developed about the potential new bundle of interventions.
We are interested in your feedback; please review the paper and send respond via our online survey: https://www.surveymonkey.com/r/anti-staphylococcalbundle by Friday 16 December 2016. We encourage you to discuss this with other relevant stakeholders in your organisation.
Data from this survey will be anonymised and aggregated and information will be used to decide the future direction of the bundle.